An update from MS Research Australia on COVID-19
19 March 2020
MS Research Australia want to share our support and provide an update on some of the actions we are taking in response to the present circumstances.
MS Research Australia want to share our support and provide an update on some of the actions we are taking in response to the present circumstances.
Wearable sensors can detect subtle changes in walking stability in people with MS, potentially making this a cheap and rapid way of detecting disease activity.
The latest DNA technology is allowing scientists to finely dissect the immune system to find what causes it to attack itself.
People with MS have a propensity to live with other medical conditions too – new findings show the impact of these on employment and work productivity.
Australian researchers have investigated how Epstein-Barr Virus might be interacting with some of the genes which influence a person’s risk of MS.
Australian researchers are one step closer to clinical trials for a treatment option that could potentially repair damage to the brain caused by MS.
Three MS treatments will be considered for inclusion on the PBS at a PBAC meeting in March – nabiximols (Sativex), siponimod (Mayzent), ozanimod (Zeposia).
The results of two international phase III clinical trials looking at the safety and effectiveness of ozanimod (Zeposia)
MS Research Australia has awarded $2.4 million in MS research grants to 19 new projects as part of $4.1 million MS research commitment for 2020.